Skoči na glavni sadržaj

Stručni rad

https://doi.org/10.2478/10004-1254-61-2010-2015

New European Commission Regulation on Variations to the Terms of Marketing Authorisation for Medicinal Products and its Impact on Croatian Legislation

Adrijana Ilić Martinac ; Agency for Medicinal Products and Medical Devices, Zagreb, Croatia
Siniša Tomić ; Agency for Medicinal Products and Medical Devices, Zagreb, Croatia
Mirna Šimičić ; Jadran Galenski Laboratorij d.d., Rijeka, Croatia


Puni tekst: engleski pdf 124 Kb

str. 311-321

preuzimanja: 738

citiraj


Sažetak

Variations introduced to medicinal product documentation must not affect the quality, efficacy, and safety of the product. Croatian Medicinal Products Act and accompanying ordinances are largely aligned with the EU regulations. The EU has now tried to simplify the issue of variations with a new Regulation, creating differences in the definition of and approach to resolving certain types of variations between Croatia and the EU. These differences could hinder the approval procedure for variations in Croatia, particularly for medicines already approved in the EU. Amending the Croatian Ordinance on medicines already authorised in the EU would be one way of maintaining the efficiency of the Croatian regulatory system.

Ključne riječi

efficacy; Medicinal Products Act; quality; registration documentation; safety

Hrčak ID:

58443

URI

https://hrcak.srce.hr/58443

Datum izdavanja:

17.9.2010.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.642 *